Recalcitrant pyoderma gangrenosum: treatment with thalidomide.

[1]  R. Powell,et al.  Guideline for the clinical use and dispensing of thalidomide. , 1994, Postgraduate medical journal.

[2]  G. Kaplan,et al.  Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation , 1993, The Journal of experimental medicine.

[3]  G. Kaplan,et al.  Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes , 1991, The Journal of experimental medicine.

[4]  M. Rustin,et al.  Pyoderma gangrenosum associated with Behçet's disease: treatment with thalidomide. , 1990, Journal of the American Academy of Dermatology.

[5]  Cox Nh,et al.  Pyoderma gangrenosum associated with Behçet's syndrome--response to thalidomide. , 1988 .

[6]  H. Koch.  Thalidomide and congeners as anti-inflammatory agents. , 1985, Progress in medicinal chemistry.

[7]  R. Barnhill,et al.  Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. , 1982, Journal of the American Academy of Dermatology.

[8]  K. Hellmann,et al.  Prolongation of Skin Homograft Survival by Thalidomide , 1965 .

[9]  J SHESKIN,et al.  Thalidomide in the treatment of lepra reactions , 1965, Clinical pharmacology and therapeutics.

[10]  G. Mellin,et al.  The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies. , 1962, The New England journal of medicine.

[11]  P. Robertson,et al.  Segmental Aspiration Pneumonia and Bronchiectasis* , 1953, British medical journal.